Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America

Walter M. Stadler, Robert A. Figlin, David F. McDermott, Janice P. Dutcher, Jennifer J. Knox, Wilson H. Miller, John D. Hainsworth, Charles A. Henderson, Jeffrey R. George, Julio Hajdenberg, Tamila L. Kindwall-Keller, Marc S. Ernstoff, Harry A. Drabkin, Brendan D. Curti, Luis Chu, Christopher W. Ryan, Sebastien J. Hotte, Chenghua Xia, Lisa Cupit, Ronald M. Bukowski

Research output: Contribution to journalArticlepeer-review

219 Scopus citations


BACKGROUND: The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) program made sorafenib available to patients with advanced renal cell carcinoma (RCC) before regulatory approval. METHODS: In this nonrandomized, open-label expanded access program, 2504 patients from the United States and Canada were treated with oral sorafenib 400 mg twice daily. Safety and efficacy were explored overall and in subgroups of patients including those with no prior therapy, nonclear cell (nonclear cell) RCC, brain metastases, prior bevacizumab treatment, and elderly patients. Sorafenib was approved for RCC 6 months after study initiation, at which time patients with no prior therapy or with nonclear cell RCC could enroll in an extension protocol for continued assessment for a period of 6 months. RESULTS: The most common grade ≥2 drug-related adverse events were hand-foot skin reaction (18%), rash (14%), hypertension (12%), and fatigue (11%). In the 1891 patients evaluable for response, complete response was observed in 1 patient, partial response in 67 patients (4%), and stable disease for at least 8 weeks in 1511 patients (80%). Median progression-free survival in the extension population was 36 weeks (95% confidence interval [CI], 33-45 weeks; censorship rate, 56%); median overall survival in the entire population was 50 weeks (95% CI, 46-52 weeks; censorship rate, 63%). The efficacy and safety results were similar across the subgroups. CONCLUSIONS: Sorafenib 400 mg twice daily demonstrated activity and a clinically acceptable toxicity profile in all patient subsets enrolled in the ARCCS expanded access program ( identifier: NCT00111020).

Original languageEnglish (US)
Pages (from-to)1272-1280
Number of pages9
Issue number5
StatePublished - Mar 1 2010


  • Bevacizumab
  • Brain metastases
  • Expanded access program
  • First-line
  • Nonclear cell
  • Progression-free survival
  • Renal cell carcinoma
  • Sorafenib

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America'. Together they form a unique fingerprint.

Cite this